The combination therapy of niraparib and abiraterone acetate (AA) could become the first dual action tablet (DAT) available in the European Union for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations. Janssen’s Akeega has been recommended for marketing authorisation when given with prednisone (P) or prednisolone by the Committee for Medicinal Products for Human Use […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
